Abstract:Abstract Background: Triple-negative breast cancer (TNBC) had been classified as a breast cancer subgroup that is negative for ER, PR and HER2. The purpose of this study was to identify prognostic factors affecting outcome in women with TNBC and to construct a prognostic model which can predict recurrence. Material and methods: We retrospectively analyzed the clinicopathologic characteristics and outcome of 284 patients diagnosed with a stage I to III triple negative breast cancer in Shanghai Cancer Hospital, including age, menopausal status, tumor size, node status, grade, ER, PR, HER-2, Cathpesin-D, PS2, Nm23, P53, Bax, Bcl-2, P27, Topo-IIa, GSTn, MDR, Cyclin D1 and Ki67. 196 patients in 2000, 2001 and 2002 belonged to training set. Prognostic significance of factors was assessed using univariate and multivariate analyses, which were combined to build a model. DFS and OS were estimated by the Kaplan-Meier method and compared among groups via the log-rank test. The prognostic value of the model was further validated in separate testing set containing 88 patients in 2003 and 2004. The median age of patients was 50 years (range, 23–85 years). 95.1% patients received cytotoxic chemotherapy after surgery; 216 (76.1%) with anthracycline based, 54 (19.0%) with CMF regimen. Results: The median follow-up duration was 70.6 months, 102 patients (35.9%) experienced recurrence or metastasis. In Cox regression, ≥4 lymph node metastasis (HR = 3.7, P < 0.001), Cath-D positive (HR = 2.1, p = 0.034), and Ki-67 index≥20%, (HR = 2.0, p = 0.006) were identified as independent factors for DFS, only ≥4 lymph node metastasis (HR = 4.9, P < 0.001) showed prognostic significance for OS. The prognostic model is based on the sum total of factors, in which ≥4+ nodes, Cath-D + or Ki-67 index≥20% would contribute 1 point separately to the risk score. According to the prognostic score, patients were assigned to low-risk group(0 and 1 point) and high-risk group(2 and 3 point). The 5-year DFS rates in two groups were 82.3% and 47.8%, respectively (p < 0.001). The model provided a high predictive accuracy of recurrence, which showed an AUC of 0.71 in the training set and an AUC of 0.70 in validation set. Conclusion: Based on nodal status, Ki-67 and Cathpesin-D, we built a model that had considerable clinical value in predicting recurrence in TNBC patients, which help clinicians guide the appropriate level of adjuvant treatment and scheduling of surveillance visits. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-07-36.

Risk Model in Stage IB1-IIB Cervical Cancer with Positive Node after Radical Hysterectomy.

A Risk-Scoring Model for Predicting Lymph Node Metastasis in Early Gastric Cancer Patients: a Retrospective Study and External Validation

An analysis on the high risk factors of pelvic lymph node metastasis in cervical carcinoma patients

Incidence and Risk Factors of Lymph Node Metastasis in Breast Cancer Patients Without Preoperative Chemoradiotherapy and Neoadjuvant Therapy: Analysis of SEER Data.

Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer

[Analysis of Prognostic Factors in Patients with Cervical Squamous Cell Carcinoma of Stage Ib and IIa].

Development And Validation Of A Surgical-Pathologic Staging And Scoring System For Cervical Cancer

The Prognosis of Women with Stage IB1-IIB Node-Positive Cervical Carcinoma after Radical Surgery

Region-specific Risk Factors for Pelvic Lymph Node Metastasis in Patients with Stage IB1 Cervical Cancer

Risk factors for lymph node metastasis and clinical outcomes in cervical cancer patients following primary radical hysterectomy: A single-center analysis of 1495 patients.

Effect Of The Number Of Removed Lymph Nodes On Survival In Patients With Figo Stage Ib-Iia Cervical Squamous Cell Carcinoma Following Open Radical Hysterectomy With Pelvic Lymphadenectomy: A Retrospective Cohort Study

Development, Verification, and Comparison of a Risk Stratification Model Integrating Residual Cancer Burden to Predict Individual Prognosis in Early-Stage Breast Cancer Treated with Neoadjuvant Therapy.

Risk Stratification of Early-Stage Cervical Cancer with Intermediate-Risk Factors: Model Development and Validation Based on Machine Learning Algorithm

Establishment of a Novel Risk Stratification System Integrating Clinical and Pathological Parameters for Prognostication and Clinical Decision‐Making in Early‐Stage Cervical Cancer

Number of Removed Pelvic Lymph Nodes as a Prognostic Marker in FIGO Stage IB1 Cervical Cancer with Negative Lymph Nodes

Abstract P6-07-36: A Prognostic Model for Triple-Negative Breast Cancer Patients Based on Node Status, Cathpesin-D and Ki-67

Establishing a Nomogram for Stage IA-IIB Cervical Cancer Patients after Complete Resection

Prognostic Factors and Survival of Stage IB-IIA Cervical Cancer.

Establishing a risk stratification model to identify clinically high-risk N0 breast cancer who could benefit from regional nodal irradiation: a single institute analysis

Prognostic value of lymph node ratio in patients with non-metastatic cervical cancer treated with radical hysterectomy: A population-based study

Topographic distribution of lymph node metastasis in patients with stage IB1 cervical cancer: an analysis of 8314 lymph nodes